Skye Bioscience, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, specializing in the development of cannabinoid-based therapies aimed at addressing significant unmet medical needs. The company leverages the therapeutic potential of the endocannabinoid system to advance a diverse pipeline targeting conditions such as glaucoma, pain management, and inflammation. With a robust commitment to scientific innovation and a focus on rigorous clinical development processes, Skye is positioning itself as a leader in the biopharmaceutical industry, dedicated to delivering effective, patient-centered treatment solutions. Show more

Location: 11250 EL CAMINO REAL, SAN DIEGO, CA, UNITED STATES, 92130, San Diego, CA, 92130, USA | Website: https://skyebioscience.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

25.63M

52 Wk Range

$0.68 - $5.75

Previous Close

$0.80

Open

$0.81

Volume

199,303

Day Range

$0.80 - $0.84

Enterprise Value

-6.979M

Cash

18.44M

Avg Qtr Burn

-13.36M

Insider Ownership

1.39%

Institutional Own.

62.68%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Nimacimab Details Obesity	Phase 2a Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Nimacimab Details Metabolic-associated steatotic liver disease (MASLD)	Phase 1b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.